Please assess the completion status of the following clinical trial:

Trial Title: The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be enrolled in CNTN~2. Aged 55 to 90~3. Available study partners~4. Willing and able to participate in longitudinal follow-up study~5. For MCI patients, fit criteria based in Movement Disorders Task Force or NIA~Exclusion Criteria:~1. Significant neurological disorders other than AD or PD;~2. Unstable medical conditions~3. History of major psychiatric diseases~4. MRI evidence of infarction or other focal lesion or multiple lacunes~5. Clinically significant abnormalities in B12 or TSH~6. Identified as having a common polymorphism (rs6971) in the TSPO gene which has been shown to reduce binding affinity of tracers similar to GE180. This testing will be done as part of their CNTN participation.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Alzheimer's Disease (Type: EXPERIMENTAL): Alzheimer's Disease~GE180 PET Scan
- Parkinson's Disease (Type: EXPERIMENTAL): Parkinson's Disease~GE180 PET Scan
- Control (Type: EXPERIMENTAL): Control Group~GE180 PET Scan
- Mild Cognitive Impairment (Type: EXPERIMENTAL): Mild Cognitive Impairment~GE180 PET Scan

Based on this trial design, predict the completion outcome and termination type (if applicable).